Effects of Stimulant Medications in PTSD

Starting soon · Phase 1 · Has a placebo group

Conditions studied: Adderall, PTSD, Post Traumatic Stress Disorder

In brief

While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.

Key facts

Study ID

NCT07664631

Run by

University of Chicago

People needed

40

Starts

2026-09-15

Expected to finish

2027-09-15

Last updated by the study team

2026-06-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18 - 65 years old
• BMI 19-30 kg/m2
• English fluency

You may not qualify if…

• Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder
• Individuals with current acute or high risk of suicide or suicide attempt in past 6 months
• Individuals with current psychotic or bipolar disorder
• Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder
• Individuals with chronic (non-PRN) treatment with antipsychotic drug (except PRN quetiapine 25mg PO qHS) or D2 antagonist
• Individuals with medications with significant PD or PK interactions
• Individuals with current treatment with a stimulant medication
• Individuals with court or legally mandated treatment
• Individuals with unstable or untreated medical disorder that would increase the risk of serious side effects of study drug (unstable hypertension, tachycardia, cardiac arrhythmia, recent MI or stroke, clinically significant neuropsychiatric or neurological disorder)
• Members of a vulnerable population
• High blood pressure (>140/90)
• Women who are pregnant, breastfeeding, or planning to become pregnant

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.